BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 19440
Title: Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer
Reviewer's code: 01981051
Reviewer's country: China
Science editor: Jin-Xin Kong
Date sent for review: 2015-05-11 15:24
Date reviewed: 2015-08-15 07:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[Y] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[Y] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Dear editor, This review addresses the p21-activated kinases (PAKs),which has been identified for years, playing an important role in the development of cancer. Signalling pathway, together with PAK members has been classified into two groups. The focus of this reviw is just to demonstrate the importance of another 3 family members (class II). Of interest, the authors has done some work in this field and has identified some problems in developing certain kinds of inhibitors. Though we are not so confident about the future application of these inhibitors, this paper presents with comprehensive and serious review in this field, including structure, biological functions, and its role in different kinds of GI cancers, as well as future applicaitons.